LY2181308

From WikiMD's Wellness Encyclopedia


LY2181308 is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.[1]

It being investigated for a number of different cancers.[2]

It is targeted at survivin which prevents cells dying.[3]

Clinical trials[edit | edit source]

It has completed a phase II trial for acute myeloid leukemia.[4]

A phase II trial for non-small cell lung cancer has started.[5]

A phase II trial for hormone-refractory prostate cancer will run until early 2012.[6]

References[edit | edit source]

  1. "Search of: LY2181308". ClinicalTrials.gov.
  2. "Cancer". Isis Pharmaceuticals. Archived from the original on 2009-10-10. Retrieved 2019-08-31. {{cite web}}: Unknown parameter |dead-url= ignored (help)
  3. "A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia". ClinicalTrials.gov.
  4. "Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer". ClinicalTrials.gov.
  5. "A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer". ClinicalTrials.gov.


LY2181308 Resources
Wikipedia
WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD